A blood pressure reducing and injection increasing active agent and its preparation method

Abstract

The present invention discloses a pressure-reducing and injection-enhancing active agent and a preparation method thereof, relating to the technical field of injection agent materials. The pressure-reducing and injection-enhancing active agent comprises the following raw materials in parts by weight: 10-15 parts of a modified betaine-type amphoteric surfactant, 30-50 parts of a cationic surfactant, 20-30 parts of nano-silica, 4-6 parts of a scale inhibitor, 1-5 parts of a stabilizer, and 100-140 parts of deionized water. The present invention prepares a first-generation polymer using hexamethylenetetramine and tromethamine, then reacts the first-generation polymer with 10-undecanol to prepare a second-generation polymer, then reacts the second-generation polymer with epichlorohydrin to prepare a graft polymer, then reacts the graft polymer with dimethylamine to obtain a light yellow intermediate, and finally reacts with sodium 3-chloro-2-hydroxypropanesulfonate to obtain a modified betaine-type amphoteric surfactant. The pressure-reducing and injection-enhancing active agent prepared by the present invention has the characteristics of a large deblocking radius and a good pressure-reducing and injection-enhancing effect.

Description

Technical Field

[0001] The invention relates to the technical field of injection-increasing agent materials, and in particular to a pressure-reducing and injection-increasing active agent and a preparation method thereof. Background Art

[0002] With the continuous exploitation of oil and gas resources, most onshore medium- and high-permeability oilfields in my country have entered the mid-to-late-stage development phase. Therefore, the efficient development of low-permeability oil and gas fields with enormous reserves and potential has become a crucial strategy for stabilizing production capacity in most oilfields for the foreseeable future. Due to poor reservoir properties, low permeability, and complex pore-throat structures, low-permeability reservoirs typically experience high water injection pressures, limited water injection, and low recovery rates during development. Conventional production and injection enhancement measures are ineffective. Currently, the main pressure-reduction and injection enhancement technologies include surfactant injection, acidizing and fracturing, and nano-polysilicon pressure-reduction and injection. Surfactant injection is the most widely used. Surfactants not only reduce oil-water interfacial tension, significantly improving oil recovery efficiency, but also improve the flow of crude oil through the formation. They mitigate the effects of wettability, water lock, and the Jamin effect on pressure, reducing injection pressure and simplifying the challenges of high-pressure water injection. Furthermore, they can increase flow velocity in low-permeability reservoirs, shortening recovery time and reducing production costs.

[0003] Chinese invention patent publication number CN111944506A discloses a blood pressure-reducing and injection-increasing active agent and its preparation method. The active agent comprises the following components: long-chain fatty acid diethanolamide, anionic surfactant, cationic surfactant, nanomaterial, additive, and water. The active agent exhibits good stability, long-term efficacy, and low adsorption capacity, but has a low blood pressure reduction rate. Summary of the Invention

[0004] In view of the shortcomings of the prior art, the present invention aims to provide a blood pressure reducing and injection increasing active agent and a preparation method thereof.

[0005] To achieve the above object, the present invention is implemented through the following technical solutions:

[0006] A blood pressure reducing and injection increasing active agent, comprising the following raw materials in parts by weight:

[0007] Modified betaine type amphoteric surfactant: 10-15 parts,

[0008] Cationic surfactant: 30-50 parts,

[0009] Nano silicon dioxide: 20-30 parts,

[0010] Antiscalant: 4-6 parts,

[0011] Stabilizer: 1-5 parts,

[0012] Deionized water: 100-140 parts;

[0013] The modified betaine type amphoteric surfactant is prepared by the following method:

[0014] S1: Hexamethylenetetramine reacts with p-aminophenol in the presence of glacial acetic acid as a catalyst to obtain a first-generation polymer. The reaction equation is as follows:

[0015]

[0016] S2: Under nitrogen protection, the first-generation polymer and 10-undecenol react in the presence of catalyst C-94 and 1-butyl-3-methylimidazolium methanesulfonate ionic liquid to obtain a second-generation polymer. The reaction equation is as follows:

[0017]

[0018] S3: Under nitrogen protection, the second-generation polymer and epichlorohydrin react under the action of KOH to obtain a grafted polymer. The reaction equation is as follows:

[0019]

[0020] S4: DMF and grafted polymer are added to the reactor in sequence, heated to 80-100°C, stirred to dissolve, and then dimethylamine is added dropwise. After thorough mixing, KOH catalyst is added, and then the temperature is raised to 120-140°C. The reaction is carried out under nitrogen protection for 6-10 hours, and vacuum distillation and column chromatography are performed to obtain a light yellow intermediate. The reaction equation is shown below:

[0021]

[0022] S5: Isopropyl alcohol, water, and sodium 3-chloro-2-hydroxypropanesulfonate are added to the reactor in sequence, stirred and dissolved, and then the light yellow intermediate and catalyst NaOH are added. The temperature is raised to reflux for reaction for 6-8 hours. After the reaction is completed, post-treatment is performed to obtain a modified betaine-type amphoteric surfactant. The reaction equation is shown below:

[0023]

[0024] The mass ratio of DMF, graft polymer, dimethylamine and KOH is 30:(6-8):(3-5):(0.1-0.12).

[0025] The mass ratio of the sodium 3-chloro-2-hydroxypropanesulfonate, the light yellow intermediate, isopropanol, water and NaOH is (2-4):(6-10):10:20:(0.1-0.3).

[0026] The cationic surfactant is one of dodecyltrimethylammonium chloride, hexadecyltrimethylammonium chloride and didodecyltrimethylammonium chloride.

[0027] The scale inhibitor is a combination of one or more of ethylenediaminetetramethylenephosphonic acid, tetrasodium aminotrimethylenephosphonic acid, and sodium benzotriazole.

[0028] The stabilizer is one or more combinations of potassium carbonate, potassium chloride and potassium humate.

[0029] A method for preparing a blood pressure-lowering and injection-increasing active agent comprises the following steps:

[0030] S1: Weigh by weight: modified betaine type amphoteric surfactant: 10-15 parts, cationic surfactant: 30-50 parts, nano-silica: 20-30 parts, scale inhibitor: 4-6 parts, stabilizer: 1-5 parts, deionized water: 100-140 parts;

[0031] S2: Add deionized water, modified betaine surfactant, cationic surfactant, nano-silica, scale inhibitor and stabilizer into the reactor in sequence, stir, slowly heat up to 35-55℃, and keep warm for 2-4h to obtain the pressure-reducing and injection-increasing active agent.

[0032] Due to the adoption of the above technical solution, the beneficial effects of the present invention include:

[0033] (1) The present invention prepares a first-generation polymer by using urotropine and tromethamine, then reacts the first-generation polymer with 10-undecanol to prepare a second-generation polymer, then reacts the second-generation polymer with epichlorohydrin to prepare a graft polymer, then reacts the graft polymer with dimethylamine to obtain a light yellow intermediate, and finally reacts with sodium 3-chloro-2-hydroxypropanesulfonate to obtain a modified betaine-type amphoteric surfactant.

[0034] (2) The modified betaine-type amphoteric surfactant prepared by the present invention has both cationic hydrophilic groups and anionic hydrophobic groups. Since the molecular structure contains a large number of hydrophilic groups, it can form more hydrogen bonds in water and has excellent water solubility; at the same time, the presence of quaternary ammonium nitrogen in the molecule has good chemical stability in acidic and alkaline media; due to the presence of sulfonic acid groups, it has good resistance to high concentrations of calcium and magnesium ions, and still has quite good stability in high concentrations of calcium and magnesium ion solutions, so it can be used in a wide pH range. Therefore, the prepared modified betaine-type amphoteric surfactant has better water solubility and higher surface activity than traditional amphoteric surfactants, effectively reduces the interfacial tension of the solution, and then reduces the flow resistance of the injected water, achieving the effect of reducing the water injection pressure, and improving the oil recovery rate of high-temperature and high-mineralization oil reservoirs. DETAILED DESCRIPTION

[0035] The present invention will be further described below with reference to the embodiments, but the present invention is not limited to these embodiments.

[0036] Example 1 Preparation of grafted polymer:

[0037] S1: 1 kg of deionized water, 0.25 kg of hexamethylenetetramine, 0.1 kg of p-aminophenol, and 0.08 kg of glacial acetic acid were added to a reactor in sequence, stirred and dissolved, heated to 75°C, reacted for 3 h, cooled to room temperature, separated, and the aqueous layer was washed three times with deionized water (using 200 g of deionized water each time) to obtain a first-generation polymer;

[0038] S2: 2 kg DMF, 0.6 kg first-generation polymer, 0.4 kg 10-undecanol, 0.008 kg catalyst C-94, and 0.006 kg 1-butyl-3-methylimidazolium methanesulfonate ionic liquid were added to the reactor in sequence under nitrogen protection. The temperature was raised to 100 ° C and reacted for 4 hours. The mixture was cooled to room temperature, 3 kg deionized water was added and stirred evenly, and the mixture was centrifuged. The mixture was washed with 0.6 kg anhydrous ethanol and then with 0.4 kg deionized water, and dried in vacuo at 70 ° C for 8 hours to obtain the second-generation polymer.

[0039] S3: 1 kg DMSO, 0.6 kg second-generation polymer, and 0.001 kg KOH were added to the reactor in sequence, stirred to dissolve, and heated to 40°C. Then, 0.18 kg second-generation polymer was added dropwise for 10 minutes. The mixture was reacted under nitrogen for 10 hours, cooled to room temperature, and centrifuged to obtain a polymer filter cake. The mixture was washed with dichloromethane three times (50 g of dichloromethane each time), and distilled under reduced pressure at 50°C for 2 hours to obtain a grafted polymer.

[0040] Example 2 Preparation of modified betaine type amphoteric surfactant:

[0041] S1: 300 g of DMF and 60 g of the grafted polymer (prepared in Example 1) were added to a reactor in sequence, the temperature was raised to 80°C, and the mixture was stirred to dissolve. Then, 30 g of dimethylamine was added dropwise for 20 minutes. After thorough mixing, 1 g of KOH catalyst was added. The temperature was then raised to 120°C, and the mixture was reacted under nitrogen for 10 hours. The mixture was then distilled under reduced pressure at 50°C for 5 hours, and separated by column chromatography to obtain a light yellow intermediate.

[0042] S2: 100 g of isopropanol, 200 g of water and 20 g of sodium 3-chloro-2-hydroxypropanesulfonate were added to the reactor in sequence, stirred to dissolve, and then 60 g of the light yellow intermediate and 1 g of catalyst NaOH were added, and the temperature was raised to reflux for reaction for 8 h. After the reaction was completed, the mixture was distilled under reduced pressure at 40 ° C for 4 h, and then 150 g of isopropanol was added to dissolve it. The mixture was dried with 100 g of anhydrous sodium sulfate for 2 h, filtered, and distilled under reduced pressure at 70 ° C for 3 h. Then, the mixture was recrystallized with ethyl acetate 3 times (using 100 g of ethyl acetate each time) and dried under vacuum at 60 ° C for 5 h to obtain a modified betaine-type amphoteric surfactant.

[0043] Example 3 Preparation of modified betaine type amphoteric surfactant:

[0044] S1: 300 g of DMF and 70 g of the grafted polymer (prepared in Example 1) were added to a reactor in sequence, the temperature was raised to 90°C, and the mixture was stirred to dissolve. Then, 40 g of dimethylamine was added dropwise for 25 minutes. After thorough mixing, 1.1 g of KOH catalyst was added. The temperature was then raised to 130°C, and the mixture was reacted under nitrogen for 8 hours. The mixture was then distilled at 60°C under reduced pressure for 4 hours, and separated by column chromatography to obtain a light yellow intermediate.

[0045] S2: 100 g of isopropanol, 200 g of water and 30 g of sodium 3-chloro-2-hydroxypropanesulfonate were added to the reactor in sequence, stirred to dissolve, and then 80 g of the light yellow intermediate and 2 g of catalyst NaOH were added, and the temperature was raised to reflux for reaction for 7 h. After the reaction was completed, it was distilled under reduced pressure at 50 ° C for 3 h, and then 150 g of isopropanol was added to dissolve it, and it was dried with 100 g of anhydrous sodium sulfate for 2 h, filtered, and distilled under reduced pressure at 80 ° C for 2 h, and then recrystallized with ethyl acetate 3 times (using 100 g of ethyl acetate each time), and dried under vacuum at 70 ° C for 4 h to obtain a modified betaine type amphoteric surfactant.

[0046] Example 4 Preparation of modified betaine type amphoteric surfactant:

[0047] S1: 300 g of DMF and 80 g of the grafted polymer (prepared in Example 1) were added to a reactor in sequence, the temperature was raised to 100° C., and the mixture was stirred to dissolve. Then, 50 g of dimethylamine was added dropwise for 30 minutes. After thorough mixing, 1.2 g of KOH catalyst was added. The temperature was then raised to 140° C., and the mixture was reacted under nitrogen for 6 hours. The mixture was then distilled under reduced pressure at 70° C. for 3 hours, and separated by column chromatography to obtain a light yellow intermediate.

[0048] S2: 100 g of isopropanol, 200 g of water and 40 g of sodium 3-chloro-2-hydroxypropanesulfonate were added to the reactor in sequence, stirred to dissolve, and then 100 g of the light yellow intermediate and 3 g of catalyst NaOH were added, and the temperature was raised to reflux for reaction for 6 h. After the reaction was completed, it was distilled under reduced pressure at 60 ° C for 2 h, and then 150 g of isopropanol was added to dissolve it. It was dried with 100 g of anhydrous sodium sulfate for 2 h, filtered, and distilled under reduced pressure at 90 ° C for 1 h. Then, it was recrystallized with ethyl acetate 3 times (using 100 g of ethyl acetate each time), and dried under vacuum at 80 ° C for 3 h to obtain a modified betaine type amphoteric surfactant.

[0049] Example 5 Preparation of blood pressure reducing and injection-increasing active agent:

[0050] (1) Weigh 10 g of a modified betaine-type amphoteric surfactant (prepared in Example 2), 30 g of a cationic surfactant (dodecyltrimethylammonium chloride), 20 g of nanosilica, 4 g of an antiscalant (ethylenediaminetetramethylenephosphonic acid), 1 g of a stabilizer (potassium carbonate), and 100 g of deionized water;

[0051] (2) Deionized water, modified betaine type amphoteric surfactant, cationic surfactant, nano-silica, scale inhibitor and stabilizer are added to the reactor in sequence, stirred, and slowly heated to 35°C, and kept warm for 4 hours to obtain the pressure-reducing and injection-increasing active agent.

[0052] Example 6 Preparation of blood pressure reducing and injection-increasing active agent:

[0053] (1) Weigh 12 g of a modified betaine-type amphoteric surfactant (prepared in Example 3), 40 g of a cationic surfactant (cetyltrimethylammonium chloride), 25 g of nanosilica, 5 g of a scale inhibitor (tetrasodium aminotrimethylenephosphonate), 3 g of a stabilizer (potassium chloride), and 120 g of deionized water;

[0054] (2) Deionized water, modified betaine type amphoteric surfactant, cationic surfactant, nano-silica, scale inhibitor and stabilizer are added to the reactor in sequence, stirred, and slowly heated to 45°C, and kept warm for 3 hours to obtain the pressure-reducing and injection-increasing active agent.

[0055] Example 7 Preparation of blood pressure reducing and injection-increasing active agent:

[0056] (1) Weigh 15 g of a modified betaine-type amphoteric surfactant (prepared in Example 4), 50 g of a cationic surfactant (didodecyltrimethylammonium chloride), 30 g of nanosilica, 6 g of a scale inhibitor (sodium benzotriazole), 5 g of a stabilizer (potassium humate), and 140 g of deionized water;

[0057] (2) Deionized water, modified betaine type amphoteric surfactant, cationic surfactant, nano-silica, scale inhibitor and stabilizer are added to the reactor in sequence, stirred, and slowly heated to 55°C, and kept warm for 2 hours to obtain the pressure-reducing and injection-increasing active agent.

[0058] Comparative Example 1

[0059] The preparation method of a blood pressure reducing and injection increasing active agent is basically the same as that of Example 6, except that no modified betaine type amphoteric surfactant is added in step (2).

[0060] Comparative Example 2

[0061] The preparation method of a blood pressure reducing and injection increasing active agent is basically the same as that of Example 6, except that the modified betaine type amphoteric surfactant added in step (2) is replaced by an equal weight of the light yellow intermediate prepared in step S1 of Example 3.

[0062] Comparative Example 3

[0063] The preparation method of a blood pressure reducing and injection increasing active agent is basically the same as that of Example 6, except that the modified betaine-type amphoteric surfactant added in step (2) is replaced by 6.5g of grafted polymer (prepared in Example 1), 3.3g of dimethylamine and 2.2g of sodium 3-chloro-2-hydroxypropanesulfonate.

[0064] Comparative Example 4

[0065] The preparation method of a blood pressure reducing and injection increasing active agent is basically the same as that of Example 6, except that the modified betaine-type amphoteric surfactant added in step (2) is replaced by an equal weight of dodecyl sulfopropyl betaine.

[0066] Comparative Example 5

[0067] The preparation method of a blood pressure reducing and injection increasing active agent is basically the same as that of Example 6, except that the modified betaine-type amphoteric surfactant added in step (2) is replaced by an equal weight of the composite surfactant prepared in step (3) of Example 2 in Publication No. CN117903774A.

[0068] Comparative Example 6

[0069] A blood pressure reducing and injection-increasing active agent is prepared using the raw materials and method of Example 2 in publication number CN111944506A.

[0070] The dodecyl sulfopropyl betaine used in the comparative example of this application is model BS-12, produced by Shengci (Hubei) Industrial Materials Co., Ltd.; the tetrasodium aminotris(methylenephosphonic acid) used in the examples and comparative examples of this application is a 30wt% aqueous solution, the ethylenediaminetetra(methylenephosphonic acid) is a 35wt% aqueous solution, and the sodium benzotriazole is a 50wt% aqueous solution, which are produced by Shandong Taihe Science and Technology Co., Ltd.; the nano-silica particle size D90 used in the examples and comparative examples of this application is 15nm, purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.

[0071] The injection agents prepared in the examples and comparative examples were subjected to surface / interfacial tension, anti-swelling performance, and core flooding experimental tests. The test results are shown in Table 1.

[0072] Determination of surface tension: Referring to the provisions of the ring method in the petroleum and natural gas industry standard "Surface and interfacial tension determination method" (SY / T5370-2018), the gas-liquid surface tension values of different surfactant solutions were measured. The experimental instrument was QBZY-2 fully automatic surface interfacial tension meter.

[0073] Determination of anti-swelling performance: According to the provisions of the industry standard "Performance Evaluation Method of Clay Stabilizers for Oil and Gas Field Fracturing, Acidizing and Water Injection" (SY / T5971-2016), the anti-swelling effect of the surfactant depressurization and injection system on the reservoir section cuttings in the target block was determined. The experimental instrument used was the KC-GDP1 high-temperature dynamic linear dilatometer.

[0074] Core flooding experiment:

[0075] 1) The natural core (length 7.5 cm, diameter 2.5 cm) was washed with oil, dried and weighed, and saturated simulated formation water (mineralization 35600 mg·L -1 ), and after 24 h of saturation, the core was taken out and weighed, and the pore volume and porosity were calculated.

[0076] 2) The core was saturated with degassed crude oil from the reservoir, and the crude oil injection rate was 0.05 mL min -1 , and then placed under the condition of reservoir temperature 80℃ for aging for 24 hours before use.

[0077] 3) Use NaCl brine with the same salinity as the injection water to displace the core at a displacement flow rate of 0.5 mL min -1 , record the pressure changes at different displacement PVs until the pressure stabilizes.

[0078] 4) Inject the surfactant solution at the same displacement flow rate and record the pressure changes.

[0079] 5) Continue to use NaCl brine to displace the core at the same displacement flow rate as before, record the change in displacement pressure, stop after displacing 20 PV, record the final displacement pressure, and calculate the pressure reduction rate.

[0080] 6) The various indicators of pressure reduction and injection performance in Table 1 are the average values of three core numbers.

[0081] Table 1

[0082]

[0083]

[0084] It can be seen from Table 1 that the anti-swelling rate of the blood pressure reducing and injection-increasing agent prepared in the present application reaches more than 95%, and the blood pressure reduction rate reaches more than 48%, indicating that the blood pressure reducing and injection-increasing agent prepared in the present application has a good blood pressure reducing and injection-increasing effect.

[0085] Comparative Example 1 is different from Example 6 in that no modified betaine-type amphoteric surfactant is added. As can be seen from Table 1, its blood pressure reduction rate is only 28.0%, and the blood pressure reduction effect is not obvious.

[0086] Comparative Example 2 is different from Example 6 in that the modified betaine-type amphoteric surfactant used is not grafted with sodium 3-chloro-2-hydroxypropanesulfonate. From the data in Table 1, it can be seen that the pressure reduction rate is 32.0%, and the pressure reduction and injection enhancement effect is poor.

[0087] Comparative Example 3 is different from Example 6, except that the modified betaine-type amphoteric surfactant used is replaced by 6.5 g of grafted polymer (prepared in Example 1), 3.3 g of dimethylamine and 2.2 g of sodium 3-chloro-2-hydroxypropanesulfonate. It can be seen from the data in Table 1 that the pressure reduction rate is 36.7%, and the pressure reduction and injection increase effect is poor.

[0088] Comparative Example 4 is different from Example 6 in that the modified betaine-type amphoteric surfactant is replaced with dodecyl sulfopropyl betaine. From the data in Table 1, it can be seen that the pressure reduction rate is 34.5%, and the pressure reduction and injection enhancement effect is poor.

[0089] Comparative Example 5 replaces the modified betaine-type amphoteric surfactant prepared in Example 3 with the composite surfactant prepared in step (3) of Example 2 in Publication No. CN117903774A. It can be seen from the data in Table 1 that the pressure reduction rate is 43.5%, and the pressure reduction and injection enhancement effect is average.

[0090] Comparative Example 6 is a blood pressure reducing and injection increasing active agent prepared using the raw materials and method of Example 2 in Publication No. CN111944506A. As can be seen from the data in Table 1, the blood pressure reduction rate is 39.5%, and the blood pressure reducing and injection increasing effect is poor.

[0091] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. However, any equivalent changes, modifications and evolutions made by ordinary technicians in this field without departing from the scope of the technical solution of the present invention by using the technical content disclosed above are all equivalent embodiments of the present invention. At the same time, any equivalent changes, modifications and evolutions made to the above embodiments based on the essential technology of the present invention are still within the scope of protection of the technical solution of the present invention.

Claims

1. A blood pressure reducing and injection increasing active agent, characterized in that: The composition comprises the following raw materials in parts by weight: Modified betaine type amphoteric surfactant: 10-15 parts, Cationic surfactant: 30-50 parts, Nano silicon dioxide: 20-30 parts, Antiscalant: 4-6 parts, Stabilizer: 1-5 parts, Deionized water: 100-140 parts; The modified betaine type amphoteric surfactant is prepared by the following method: S1: Hexamethylenetetramine reacts with p-aminophenol in the presence of glacial acetic acid to produce a first-generation polymer. S2: Under nitrogen protection, the first-generation polymer and 10-undecenol react in the presence of catalyst C-94 and 1-butyl-3-methylimidazolium methanesulfonate ionic liquid to obtain the second-generation polymer; S3: Under nitrogen protection, the second-generation polymer and epichlorohydrin react under the action of KOH to obtain a grafted polymer; S4: DMF and the grafted polymer are added to the reactor in sequence, heated to 80-100°C, stirred to dissolve, and then dimethylamine is added dropwise. After thorough mixing, KOH catalyst is added, and then the temperature is raised to 120-140°C. The reaction is carried out under nitrogen protection for 6-10 hours, and the mixture is distilled under reduced pressure and separated by column chromatography to obtain a light yellow intermediate. S5: Isopropyl alcohol, water, and sodium 3-chloro-2-hydroxypropanesulfonate are added to the reactor in sequence, stirred to dissolve, and then the light yellow intermediate and catalyst NaOH are added. The temperature is raised to reflux for reaction for 6-8 hours. After the reaction is completed, post-treatment is performed to obtain a modified betaine-type amphoteric surfactant.

2. A blood pressure reducing and injection increasing active agent according to claim 1, characterized in that: In step S4, the mass ratio of DMF, graft polymer, dimethylamine and KOH is 30:(6-8):(3-5):(0.1-0.12).

3. The blood pressure reducing and injection-increasing active agent according to claim 1, characterized in that: In step S5, the mass ratio of the sodium 3-chloro-2-hydroxypropanesulfonate, the light yellow intermediate, isopropanol, water, and NaOH is (2-4):(6-10):10:20:(0.1-0.3).

4. The blood pressure reducing and injection-increasing active agent according to claim 1, characterized in that: The cationic surfactant is one of dodecyltrimethylammonium chloride, hexadecyltrimethylammonium chloride and didodecyltrimethylammonium chloride.

5. The blood pressure reducing and injection-increasing active agent according to claim 1, characterized in that: The scale inhibitor is a combination of one or more of ethylenediaminetetramethylenephosphonic acid, tetrasodium aminotrimethylenephosphonic acid, and sodium benzotriazole.

6. The blood pressure reducing and injection increasing active agent according to claim 1, characterized in that: The stabilizer is a combination of one or more of potassium carbonate, potassium chloride and potassium humate.

7. A method for preparing the blood pressure reducing and injection-increasing agent according to any one of claims 1 to 6, characterized in that: The following steps are involved: (1) Weigh by weight: modified betaine type amphoteric surfactant: 10-15 parts, cationic surfactant: 30-50 parts, nano-silica: 20-30 parts, scale inhibitor: 4-6 parts, stabilizer: 1-5 parts, deionized water: 100-140 parts; (2) Deionized water, modified betaine surfactant, cationic surfactant, nano-silica, scale inhibitor, and stabilizer are added to the reactor in sequence, stirred, and slowly heated to 35-55°C, and kept warm for 2-4 hours to obtain the pressure-reducing and injection-increasing active agent.

Images